CARMAT reaches 50 artificial heart implants, eyes growth in 2024 By Investing.com
[ad_1]
© Reuters.
PARIS – CARMAT (Euronext Growth:ALCAR), a French MedTech company specializing in advanced total artificial heart solutions, has announced a significant milestone with 50 implants of its Aeson® artificial heart since the first procedure in December 2013. The company, which celebrated its 15th anniversary in 2023, also reported a substantial increase in sales in the fourth quarter of 2023, with 11 of the 17 implants for the year occurring in that period, resulting in a turnover of €2.8 million.
The Aeson® heart represents a breakthrough in the treatment of advanced biventricular heart failure, offering a therapeutic alternative to heart transplants. The device is unique in its ability to adapt blood flow in real time to the patient’s needs, without the risk of rejection or a heavy drug regimen.
Throughout 2023, CARMAT expanded its commercial reach, training 41 hospitals across 12 countries to perform Aeson® implants. The company’s manufacturing capacity has also increased, with the potential to produce up to 500 artificial hearts annually, starting early 2024. This expansion corresponds to a projected annual sales potential of around €100 million.
CARMAT’s Aeson® has been supported by leading cardiologists in Europe and the United States and is becoming a reference solution for patients eligible for transplantation. The company has enhanced the device’s safety profile with software improvements that automatically correct potential malfunctions, ensuring uninterrupted patient support.
Looking forward to 2024, CARMAT anticipates sales between €14 million and €20 million, with plans to train approximately fifty hospitals for commercial implants by year-end. The company also aims to carry out around thirty implants as part of the EFICAS study in France and reduce its cash burn by about 20% compared to 2023.
CARMAT’s long-term ambition is to make Aeson® a “destination therapy” device, a long-term support solution for patients not eligible for heart transplants. The company believes that Aeson® is the only existing device with the potential to fulfill this role due to its biocompatibility and safety profile.
To support its objectives, CARMAT will soon launch a capital increase to extend its cash runway beyond the end of January 2024 and partially finance its needs for the upcoming 12 months, estimated to require a minimum of €50 million.
This news is based on a press release statement from CARMAT, detailing the company’s achievements and forward-looking plans.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
[ad_2]
Source link
© Reuters.
PARIS – CARMAT (Euronext Growth:ALCAR), a French MedTech company specializing in advanced total artificial heart solutions, has announced a significant milestone with 50 implants of its Aeson® artificial heart since the first procedure in December 2013. The company, which celebrated its 15th anniversary in 2023, also reported a substantial increase in sales in the fourth quarter of 2023, with 11 of the 17 implants for the year occurring in that period, resulting in a turnover of €2.8 million.
The Aeson® heart represents a breakthrough in the treatment of advanced biventricular heart failure, offering a therapeutic alternative to heart transplants. The device is unique in its ability to adapt blood flow in real time to the patient’s needs, without the risk of rejection or a heavy drug regimen.
Throughout 2023, CARMAT expanded its commercial reach, training 41 hospitals across 12 countries to perform Aeson® implants. The company’s manufacturing capacity has also increased, with the potential to produce up to 500 artificial hearts annually, starting early 2024. This expansion corresponds to a projected annual sales potential of around €100 million.
CARMAT’s Aeson® has been supported by leading cardiologists in Europe and the United States and is becoming a reference solution for patients eligible for transplantation. The company has enhanced the device’s safety profile with software improvements that automatically correct potential malfunctions, ensuring uninterrupted patient support.
Looking forward to 2024, CARMAT anticipates sales between €14 million and €20 million, with plans to train approximately fifty hospitals for commercial implants by year-end. The company also aims to carry out around thirty implants as part of the EFICAS study in France and reduce its cash burn by about 20% compared to 2023.
CARMAT’s long-term ambition is to make Aeson® a “destination therapy” device, a long-term support solution for patients not eligible for heart transplants. The company believes that Aeson® is the only existing device with the potential to fulfill this role due to its biocompatibility and safety profile.
To support its objectives, CARMAT will soon launch a capital increase to extend its cash runway beyond the end of January 2024 and partially finance its needs for the upcoming 12 months, estimated to require a minimum of €50 million.
This news is based on a press release statement from CARMAT, detailing the company’s achievements and forward-looking plans.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
About The Author
